This study investigates unresolvable pancreatic cancer. It focuses on the safety and effectiveness of using autologous drug-loaded neutrophils, called NeuMed, in treating this condition.
The study evaluates how well these neutrophils, which are loaded with a special drug, work against tumors. It looks at the safety of using this approach in patients with unresolvable pancreatic cancer.
- Who can participate: Participants aged 18 to 70 with unresolvable pancreatic cancer confirmed by histopathology can join if they have tried standard treatments without success or opted for this therapy voluntarily.
- Study details: Participants will receive therapy using autologous drug-loaded neutrophils. These neutrophils are isolated and prepared in a special lab. A placebo is not involved in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand